Cyberonics Q1 Epilepsy Sales Up 16%; Firm Continues To Ramp Up R&D Spend
This article was originally published in The Gray Sheet
Executive Summary
Epilepsy devicemaker Cyberonics reported 19% growth in U.S. epilepsy sales to $30.7 million for the first quarter of 2010 (ended July 24)
You may also be interested in...
FDA May Impose More "522" Studies As Post-Approval Enforcement Tool
FDA says it will more frequently use its authority to mandate so-called Section 522 post-market studies when companies fail to meet their original post-approval study requirements - and this time, the idea might actually stick
FDA May Impose More "522" Studies As Post-Approval Enforcement Tool
FDA says it will more frequently use its authority to mandate so-called Section 522 post-market studies when companies fail to meet their original post-approval study requirements - and this time, the idea might actually stick
Research In Brief
CircuLite: NIH will grant CircuLite up to $3.7 million in a Fast-Track Phase I-II Small Business Innovation Research Grant to develop a pediatric circulatory assist device based on the same technology as the firm's Synergy Pocket Micro-pump, a small impeller-driven ventricular assist device about the size of a AA battery. Saddle Brook, N.J.-based CircuLite will collaborate with the University of Maryland School of Medicine on the project. CircuLite is currently conducting a European trial of Synergy Pocket Micro-pump (1"The Gray Sheet" Sept. 17, 2007)